Leukemia  >>  dociparstat sodium (CX-01)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
PGX-AML, NCT02056782: A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia

Completed
1
12
NA
Dociparstat sodium, dociparstat, ODSH, CX-01, 2-O, 3-O desulfated heparin
Chimerix, Translational Drug Development
Acute Myeloid Leukemia
02/15
06/15
NCT01843634: Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

Completed
1
10
US
ODSH
Chimerix
Acute Myeloid Leukemia
04/15
04/15
NCT02995655: CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Completed
1
20
US
CX-01, 2-O, 3-O desulfated heparin, ODSH, Azacitidine, Vidaza®, Ladakamycin, Bone marrow biopsy, Peripheral blood draw
Washington University School of Medicine, Cantex Pharmaceuticals
Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
09/18
04/19

Download Options